anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a traditional Chinese medicine composition formula for treating chronic heart failure by promoting expression of a sarcoplasmic reticulum calcium pump, which comprises the following raw material medicines: monkshood, astragalus root, zedoary and ophiopogon root. In addition, the invention also discloses a traditional Chinese medicine composition formula for treating chronic heart failure by promoting the expression of the sarcoplasmic reticulum calcium pump, which comprises the following raw material medicines: prepared aconite root, astragalus root, zedoary and ophiopogon root. Correspondingly, the invention also discloses a traditional Chinese medicine preparation for treating chronic heart failure by promoting the expression of the sarcoplasmic reticulum calcium pump, which is prepared from the formula of the traditional Chinese medicine composition, and the traditional Chinese medicine preparation is at least one of decoction, powder, tablets, granules or capsules. In addition, the invention discloses a preparation method of the traditional Chinese medicine preparation for treating chronic heart failure by promoting the expression of the sarcoplasmic reticulum calcium pump. In addition, the invention also discloses the application of the formula of the traditional Chinese medicine composition and the application of a traditional Chinese medicine preparation. The formula of the traditional Chinese medicine composition effectively promotes the expression of the sarcoplasmic reticulum calcium pump to treat CHF.
Expert-based intervention concept with teachers as multipliers to promote physical activity-related health competence (PAHCO). We will develop a specific intervention concept for the implementation of the curriculum content "PAHCO" at nursing schools in Bavaria from April to November 2023. Currently (March 2022), it is planned that the intervention will comprise 12 sessions with a duration of 45 or 90 minutes. The entire intervention will be specified during the different steps of intervention mapping (i.e., needs assessment, goal formulation, screening evidence-based intervention content). Teachers of the participating nursing schools of this study arm will be trained to implement this expert-based intervention concept in their school from December 2023 to March 2024.
A novel process for the oxidation of olefins to the corresponding alpha-epoxy alcohols which can be incorporated in the total synthesis of members of a novel class of prostaglandin analogues. Olefins are reacted with singlet oxygen in the presence of a group IVB, VB or VIB transition metal catalyst, excluding chromium. The reaction is fast and highly selective to the alpha-epoxy alcohol. When cyclopentene is oxidized in the process of the invention, high yields of cis 2,3-epoxy-cyclopentan-1-ol are obtained. The latter compound is used as a starting material in the synthesis of prostaglandin analogues. The prostanoids of the invention are characterized by an oxa group replacing the methylene group at the 7-position, and the absence of a hydroxyl or other substituent at the 11-position. Members of this class of prostanoids show important cytoprotective properties in animal tests.
Anthralin analogues containing a thio-substituent, especially in one or more of the positions 2-, 7- and 10- of the anthralin ring. They may be made by reacting an anthralin derivative (e.g. 10-bromoanthralin) with a thiol or a compound containing a group convertible to a thio-group. Alternatively, a 1,8-dihydroxy anthraquinone containing a thio-substituent may be reduced. Reactive intermediates may be made by introducing one or more nuclear allylic groups into a 1,8-dihydroxy anthraquinone and then converting them into a reactive form, e.g. by epoxidation or halide addition. The intermediate can then be reduced to the oxidation state corresponding to anthralin. Additional products having the 10-carbon atom of the anthralin ring as part of a heterocyclic ring, may be made by anthralins containing various substitutes thioalkyl groups as the 10-substituent. The compounds are useful for treatment of psoriasis, and may be formulated in the conventional vehicles for topical application, for example petrolatum.
OBJECTIVE: Pain is a common reason for attendance to the emergency department; however, pediatric specific data on the prevalence, location, and etiology of painful presentations are limited in the literature. Therefore, the objective of this study was to determine the prevalence of pain-related presentations to pediatric emergency departments during the triage process and characterize the anatomical locations and organ systems most affected by pain in a modern cohort.
METHODS: A two-center health record review of triage documentation was conducted at Canadian pediatric emergency departments. All children (< 18 years) were eligible for inclusion. Data were extracted from administrative sources with one week of consecutive patients included every 3 months over a one-year timeframe. Regression analyses were completed to identify variables associated with painful presentations and analgesia provision during the triage process.
RESULTS: A total of 7208 emergency department presentations were included. Median [IQR] child age was 5.2 [1.9, 11.8] years and 53.2% were male. 58.8% of children were found to have pain as a component of their triage presentation. Of those with pain (n = 4237), 24.1% had a pain score documented and 13.8% had analgesia provided at triage. Location of pain (n = 4523) was predominantly in the head (38.0%), extremities (27.8%), and abdomen (22.8%). Primary organ systems most affected (n = 4237) included the musculoskeletal (31.1%), gastrointestinal (18.3%), and cutaneous (including lacerations) (14.4%) systems.
CONCLUSIONS: In this study, pain was identified in almost 60% of all pediatric emergency department presentations at the time of triage. Suboptimal documentation of pain scores and provision of analgesia at triage were found for children with pain. These results support early assessment and implementation of pain management strategies at triage. Results can also focus further research efforts to the management of the most commonly presenting types of pediatric pain.
Comorbidities are prevalent in digestive cancers, intensifying patient discomfort and complicating prognosis. Identifying potential comorbidities and investigating their genetic connections in a systemic manner prove to be instrumental in averting additional health challenges during digestive cancer management. Here, we investigated 150 diseases across 18 categories by collecting and integrating various factors related to disease comorbidity, such as disease-associated SNPs or genes from sources like MalaCards, GWAS Catalog and UK Biobank. Through this extensive analysis, we have established an integrated pleiotropic gene set comprising 548 genes in total. Particularly, there enclosed the genes encoding major histocompatibility complex or related to antigen presentation. Additionally, we have unveiled patterns in protein-protein interactions and key hub genes/proteins including TP53, KRAS, CTNNB1 and PIK3CA, which may elucidate the co-occurrence of digestive cancers with certain diseases. These findings provide valuable insights into the molecular origins of comorbidity, offering potential avenues for patient stratification and the development of targeted therapies in clinical trials.
The immunoassay comprises (1) collection of, or formation of, on an active support, an immune complex having an enzyme component comprising the analyte (I) bound to an antibody; (2) contact of the enzyme component with signal generating agents to form a prod. (when it is a chromophore, it must be soluble in the assay medium); and (3) interaction of the prod. with the support to result in the concn. of a detectable signal on it. The immune complex may be formed in soln. by pre-incubation of (I) with an enzyme-labelled anti-analyte antibody, and it is then collected on the support. It may be formed on the support by immunochemical capture of (I) by an anti-analyte antibody bound to the support, followed by reaction with an enzyme-labelled anti-analyte antibody. Also it may be formed by capture of enzyme-labelled anti-analyte antibody by (I) bound to the support etc. The prod. formed in step (2) may be soluble in the assay medium and capable of emitting a detectable signal. The support may be made of nylon, cellulose nitrate, ethylcellulose or modified polyamide, esp. in a disc-like shape. By the technique (I) can be determined rapidly and with sensitivity, esp. when (I) is an antigen of viral or bacterial origin. (I) may also be a hapten, cells, microorganisms and their prods. in biological samples.
AB1 is the investigational product in this study taken orally, once daily, for 8 weeks. This will be an open-label, dose escalating study with a starting dose of 2mg. Up to 6 additional cohorts will be enrolled at subsequently higher doses of 4mg, 8mg, 10 mg, 12 mg, 16mg, and 32mg.
FIELD: organic chemistry, biochemistry, medicine, pharmacy. SUBSTANCE: invention describes the novel compound of the formula (I):   that is a crystalline salt of derivative of azapeptide monosulfate. The compound shows high rate of water solubility, significantly improved oral bioavailability in its administration in animals as compared with a free base. Invention describes a pharmaceutical composition comprising compound of the formula (I) as an active component. EFFECT: new compound indicated above, valuable properties. 2 cl, 5 dwg, 4 ex
Urethral pain syndrome (UPS) is characterized by recurrent or persistent symptoms such as urethral or pelvic pain, daytime frequency and nocturia with unclear aetiology are diagnosed as UPS. Chronic infection by fastidious bacteria leading to chronic inflammation and pain may also cause UPS. Due to the unclear aetiology, the optimal treatment is challenging. It is therefore essential to find new and effective treatment options for patients suffering from UPS. Over the last few years, the use of lasers has become more popular to treat gynaecological and urogynecological conditions including stress urinary incontinence (SUI), genitourinary syndrome of menopause (GSM), vaginal prolapse and other conditions. In several trials, vaginal laser therapy has been shown to have a very good effect on SUI and GSM. Very few publications are available on the use of intraurethral laser therapy for the treatment of SUI and GSM with promising results. This is the first study to test the effect of intraurethral and vaginal laser therapy for the treatment of UPS. The hypothesis is that symptoms can be relieved in patients with UPS i.e. a reduction of urethral pressure pain upon palpation can be achieved.
Following the baseline assessment, subjects will enter an open treatment group with Olanzapine(Zyprexa) lasting 6 weeks. The subjects will start with a dose of 5-10mg/d , which would be adjusted to as low as 10 mg/d or as high as 20 mg/d, based on clinical response.And drug dose adjustments must be completed within 1 week.
FIELD: natural-origin drugs. SUBSTANCE: suppository is composed of propolis extract, buckwheat honey, emulsifier, cacao oil enriched with lipids to level of carotinoids at least 1.0 mg%. Such suppository shows elevated antiinflammatory and antibacterial activities, facilitated storage and utilization. It rapidly melts in human body at 36.6 C and, at the same time, is infusible at room temperature. EFFECT: increased therapeutic effect and improved consumer's properties. 3 tbl
PURPOSE:To provide an antilipemic agent containing 24,25-dihydrocholecalciferol as an active component, and having antilipemic activity and high safety. CONSTITUTION:The objective antilipemic agent contains 24,25-dihydroxycholecalciferol (abbreviated as the present substance) of e.g. formula I . The present substance has been already known to have antihypercalcemic and antitumor activities, etc., however, it has been newly found that the compound also has antilipemic activity. It is useful as an active component of antilipemic agent, remedy for arteriosclerosis, and remedy for hydperlipemia. The active component is preferably 24R,25-(OH)2-D3 of formula II. In contrast with the activated vitamin D3 analog, the present substance has extremely high safety. Dose: preferably 0.5-1X10<4>mug/day.
The present invention is health care liquid and is one kind of Chinese medicine composition for preventing and treating rheumatism. The present invention includes two recipes. The recipe I for preventing rheumatism consists of nine kinds of Chinese medicinal materials including fossil fragments, clematis root, angelica, etc. crystal sugar, white liquor and yellow wine. The recipe II for treating rheumatism has three increased Chinese medicine materials including nux vomica seed, safflower and peach kernel on the basis of the recipe I. The medicine of the recipe II has even high treating effect.
The invention discloses preparation of an alpha-conotoxin MI antigen and application of immune serum or antibody thereof. The alpha-conotoxin MI consists of 14 amino acids. The MI-bovine serum albumin coupled antigen is prepared through a click reaction, and MI alkynyl-containing polypeptide and azidoacetic acid modified BSA carrier protein are subjected to a click reaction to form the MI-coupled carrier protein antigen. The epitope of the protein carrier coupling antigen is not affected, the immunogenicity is high, and after Balb/c mice and horses are immunized, the antibody titer of mouse antiserum and horse antiserum antibody shown by MI-coated ELISA is high. The MI antiserum, the antibody and MI incubated neutralizing activity experiment and the MI administered antiserum injected detoxifying activity experiment show that the prepared MI antiserum and antibody have high neutralizing activity and detoxifying activity. The MI-protein coupled antigen prepared by the method can be used for preparing or screening antiserum or antibody, and the antiserum or the antibody is used for detoxifying and detecting alpha-conotoxin MI and analogues.
A superoxide dismutase  is  produced  by  serratia  sp.  Y-4, donation No.KFCC 8276P. The dismutase has a mol. wt. of 54000. The strain is cultured on a seed medium at 28 deg.C with  shaking  for 18-24 hrs, seeded to fermentation medium by 5% at an air  flow  of 0.3-1.0 VVm and a stirring rate of 350-450 rpm.  and  cultured  at 27-31 deg.C for 8 hrs. The strain is cultured  further  for  18-22 hrs. but with the stirring rate dropped to 200-300  rpm.  paraquat is added with a ratio of 0.5 mM as a inducing substance within the initial 6 hrs. The dismutase is separated and  purifyed  from  the culture cells. The dismutase is useful as antiinflammatory agent.
Common variable immunodeficiency (CVID) is the most prevalent primary immunodeficiency, marked by hypogammaglobulinemia, poor antibody responses, and increased infection susceptibility. The COVID-19 pandemic provided a unique opportunity to study the effects of prolonged viral infections on the immune responses of CVID patients. Here we use single-cell RNA-seq and spectral flow cytometry of peripheral blood samples before, during, and after SARS-CoV-2 infection showing that COVID-19 CVID patients display a persistent type I interferon signature at convalescence across immune compartments. Alterations in adaptive immunity include sustained activation of naïve B cells, increased CD21low B cells, impaired Th1 polarization, CD4+ T central memory exhaustion, and increased CD8+ T cell cytotoxicity. NK cell differentiation is defective, although cytotoxicity remains intact. Monocytes show persistent activation of inflammasome-related genes. These findings suggest the involvement of intact humoral immunity in regulating these processes and might indicate the need for early intervention to manage viral infections in CVID patients.
1455884 Telescopic capsules LILLY INDUSTRIES Ltd 12 Feb 1974 [14 Feb 1973] 7141/73 Heading B8C Telescopic capsules, e.g. for pharmaceutical use are comprised of conventionally shaped body and cap portions, both of which are composed of two superposed layers of different materials which are soluble in aqueous media in different but overlapping pH ranges. Both portions are manufactured separately, e.g. by a conventional dipping progress wherein the body and cap pins are dipped successively in solutions of the two materials. Subsequent to manufacture of the separate body and cap portions, the capsules may be filled, closed and sealed by application of a circumferential band at the junction of cap and body e.g. of the same material as the outer layer of the capsule walls. Suitable materials for the first (inner) layer are; gelatin (preferred), calcium alynate, methyl cellulose and hydroxy cellulose-alkyl cellulose ethers. Suitable materials for the outer layer are; salol, benzoin, nbutyl stearate, carnuba wax, shellac, methacrylis acid polymers, carboxyvinyl polymers, maleic anhydride-vinyl alkyl ether or alkene copolymers and cellulose derrivates. For medicaments, these which are substantially insoluble below about pH 3À5 are preferred, these giving enteric capsules.
[GB1455884A]
OBJECTIVE: To investigate changes in depressive and suicidality status and their relationship with seizure outcomes after the addition or substitution of another antiseizure medication (ASM) in adults with drug-resistant focal epilepsy.
METHODS: Seven hundred seventy consecutively enrolled patients were assessed and followed prospectively for seizure outcome and depressive status over a 6-month period after starting treatment with a newly introduced ASM. The Neurological Disorders Depression Inventory for Epilepsy (NDDIE) was used to screen for depression and suicidality. Correlations of NDDIE results with clinical and treatment-related variables were assessed by using a stepwise logistic regression model.
RESULTS: At baseline, 50% of patients had a positive screening test result for depression and 13% had a positive screening test result for suicidal ideation. A psychiatric comorbidity at baseline was associated with a 2.3 times increased risk of an initially negative NDDIE screening result becoming positive at re-assessment after 6 months. In addition, the number of ASMs taken at baseline correlated with an increased risk of a change in depression screening test results from negative to positive during follow-up, whereas no association was identified with sociodemographic and epilepsy-related variables, including seizure outcomes. Approximately 6% of patients who were initially negative at screening for suicidal ideation became positive at the 6-month re-assessment. The risk of switch from a negative to a positive screening test result for suicidal ideation was increased more than two-fold in individuals who screened positive for depression at baseline, and was unrelated to the type of ASM introduced, sociodemographic variables, or seizure outcomes.
SIGNIFICANCE: Almost 1 in 5 adults with drug-resistant focal epilepsy who screen negative for depression become positive when re-assessed 6 months after a treatment change. At re-assessment 6 months later, 6.1% who screen initially negative for passive suicidal ideation become positive. These changes in screening status are independent of type of ASM introduced or seizure outcomes but correlate with psychiatric status at baseline.
Patients receive ABVD chemotherapy comprising doxorubicin hydrochloride IV, bleomycin IV, vinblastine IV, and dacarbazine IV on days 1 and 15. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
FIELD: medicine; pharmaceutics.SUBSTANCE: invention relates to pharmaceutical industry, namely to a stable Pickering emulsion. Stable Pickering emulsion, which is a heterogeneous system consisting of two immiscible liquids, in which one liquid is uniformly distributed throughout the volume of the other liquid in the form of oil drops stabilized by nanocrystalline cellulose particles, characterized by that the first liquid in the form of drops is Vaseline or olive oil, and the second is a hydrosol with content of acylated nanocrystalline cellulose (ACNCC) in amount of 0.2–1.6 wt. % with zeta potential of particles minus 36–40 mV, particle size along length from 135 nm to 205 nm and cross section - from 6 nm to 10 nm, wherein in an emulsion consisting of a dispersion aqueous medium and oil drops, the components are distributed at the following volume ratio: hydrosol - 70 %; vaseline or olive oil - 30 %, wherein the surface of the oil drops in the emulsion has a negative zeta potential, the zeta potential of the drop for the emulsion with Vaseline oil minus 6.9, minus 7.5, minus 9.6, minus 10.3 or minus 12.5, for emulsion with olive oil - minus 10.9, minus 11.9, minus 17.7, minus 18.5 or minus 19.9. Method of producing stable Pickering emulsions, comprising emulsifying two immiscible liquids until one liquid is evenly distributed throughout the volume of the other liquid to form oil drops stabilized in the volume, characterized by that emulsification is carried out with ultrasound until the oil is uniformly distributed throughout the volume of the hydrosol in the form of oily drops using an ultrasonic generator IL-10-0.1 for 180 seconds with frequency of 22 kHz, stabilization of the surface of oil drops is carried out with particles of ACNCC with a zeta potential of particles of minus 36–40 mV, with length of 135 nm to 205 nm and a cross section of 6 nm to 10 nm, wherein during emulsification of vaseline or olive oil and hydrosol containing ACNCC in amount of 0.2–1.6 wt. %, obtaining a stable shell on the surface of drops with a negative zeta potential: for an emulsion with Vaseline oil minus 6.9, minus 7.5, minus 9.6, minus 10.3 or minus 12.5, for emulsion with olive oil - minus 10.9, minus 11.9, minus 14.0, minus 17.7, minus 18.5 or minus 19.9. Disclosed is the use of an emulsion which is stable under conditions of the stomach as a target delivery system of lipophilic drugs when administered orally.EFFECT: emulsion described above is a gastric-stable lipophilic drug delivery system; the method for preparing the emulsion is effective and simple; it enables to form a stable coating of emulsified drops.4 cl, 5 dwg, 3 tbl, 20 ex
Either 25 mg of Alteplase or Placebo instilled daily. Response to therapy after three days. cross over to the other drug if no response was noted.
Succinylcholine Chloride Injection, USP is a sterile, nonpyrogenic solution to be used as a short-acting, depolarizing neuromuscular blocker for intravenous or intramuscular use. Succinylcholine Chloride Injection contains succinylcholine chloride as the active pharmaceutical ingredient.

Succinylcholine Chloride, USP is chemically designated as Ethanaminium, 2,2’-[(1,4-dioxo-1,4-butanediyl) bis(oxy)]bis[N, N, N-trimethyl-, dichloride, dihydrate, it’s molecular formula is C14H30Cl2N2O4•2H2O and its molecular weight is 397.34. 

It has the following structural formula:

Structural Formula

Succinylcholine is a diquaternary base consisting of the dichloride salt of the dicholine ester of succinic acid. It is a white, odorless, slightly bitter powder, very soluble in water. The drug is incompatible with alkaline solutions but relatively stable in acid solutions. Solutions of the drug lose potency unless refrigerated.

Succinylcholine Chloride Injection, USP 100 mg/5 mL (20 mg/mL) is intended for single-dose administration and contains no preservatives. Unused solution should be discarded. Product not requiring dilution (single-dose prefilled syringe) contains sodium chloride to render isotonic. Each milliliter contains 20 mg succinylcholine chloride USP equivalent to 21.99 mg succinylcholine chloride dihydrate, and 4.5 mg of sodium chloride as an isotonicity agent. May contain sodium hydroxide and/or hydrochloric acid for pH adjustment. The pH of the solution is 3.6 (3.0 to 4.5).